Navigation Links
Jefferson researcher awarded Landenberger Foundation grant for ALS research

PHILADELPHIA Piera Pasinelli, Ph.D., co-director of the Frances and Joseph Weinberg Unit for ALS Research at the Farber Institute for Neurosciences at Thomas Jefferson University was recently awarded a Margaret Q. Landenberger Research Foundation grant to identify why drug therapies that showed promise in Amyotrophic Lateral Sclerosis (ALS) mouse models have proven unsuccessful in human clinical trials. Dr. Pasinelli and her research team will closely examine critical aspects of drug delivery in the central nervous system at the metabolic level with the hope of advancing drug development for ALS. The grant totals $300,000 and will be issued in $100,000 disbursements over three years.

"In spite of recent progress toward understanding the origination of ALS, finding an effective treatment has remained elusive. Our hypothesis is that one reason there is no viable drug therapy for ALS may be that in designing both mouse and human clinical trials, scientists have overlooked critical aspects of drug bioavailability and metabolism." said Dr. Pasinelli. "Proteins called multi-drug resistance transporters are increased during the disease, rendering pharmacological treatments for ALS mostly ineffective. This grant will support research towards finding ways to inactivate these transporter proteins to counteract their negative effect on ALS therapy. We are extremely grateful to the Margaret Q. Landenberger Research Foundation for seeing the potential our work has and awarding us this grant money."

The Margaret Q. Landenberger Research Foundation, which was formed in 1992, is based in Philadelphia, Pennsylvania. Brown Brothers Harriman Trust Company, N.A., serves as the foundation's corporate trustee.

"The Landenberger Foundation provides initial funding for novel medical research projects in the hope that this will help the scientists further expand their research through additional grants from other sources," said William R. Levy, Executive Vice President, who oversees the operations of the foundation for the Brown Brothers Harriman Trust Company. "Although it is a small foundation, it has an excellent scientific advisory board that helps direct the grant-making decisions. The Foundation's mission is to be at the cutting edge of medical research."

ALS, commonly known as Lou Gehrig's disease or motor neuron disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed. According to the ALS Association, every year about 5,600 people are diagnosed with the disease, which is currently untreatable.


Contact: Ed Federico
Thomas Jefferson University

Related biology news :

1. Jefferson scientists discover a key protein regulator of inflammation and cell death
2. Jefferson Department of Surgery announces new pancreas tumor registry
3. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
4. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
5. Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
6. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
7. CSHL researchers explain process by which cells hide potentially dangerous DNA segments
8. ISU researcher identifies protein that concentrates carbon dioxide in algae
9. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
10. Biomedical researchers invited to design experiments for the International Space Station
11. Caltech researchers train computers to analyze fruit-fly behavior
Post Your Comments:
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list ... facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up ...
Breaking Biology Technology: